Fluor to support Agilent’s $725m life sciences facility expansion in Colorado

TAGS

Fluor Corporation, through its Advanced Technologies & Life Sciences business, will support the expansion of ‘ manufacturing plant in , .

Under the contract, will provide architectural and engineering services and procure equipment for the $725 million expansion project that is anticipated to double Agilent Technologies’ manufacturing capacity of nucleic acids therapeutics, also known as oligonucleotides or oligos.

The new 275,000 square-foot manufacturing plant will include two manufacturing lines and produce siRNA, antisense molecules, and CRISPR guide RNA molecules.

Juan Hernández — Fluor’s Advanced Technologies & Life Sciences business president said: “We will incorporate state-of-the-art engineering enhancements such as advanced automation, water reduction strategies and solvent capturing to optimize cost and construction.

See also  G42 Healthcare begins phase 3 trial of Sinopharm COVID-19 inactivated vaccine candidate in UAE

“This enables us to fast-track the project so that Agilent can meet its global customers’ needs by getting products to market faster.”

Fluor to support the life sciences facility expansion of Agilent Technologies in Colorado

Fluor to support the life sciences facility expansion of Agilent Technologies in Colorado. Photo courtesy of Business Wire.

The project is expected to enhance the US manufacturing capacity for active pharmaceutical ingredients and provide over 160 life science jobs in the Frederick area.

See also  Wipro, Transcell Oncologics to transform safety assessment of vaccines

Mike McMullen — Agilent Technologies CEO said: “Agilent has had a growing presence in Colorado for more than 20 years.

“We are very excited about this next phase of investment in this rapidly growing area of biotechnology.

“We’re proud to be helping to drive this growth by creating innovative therapeutics that improve the quality of life.”

Agilent Technologies also contracted North America-based construction services company Turner to build the pharmaceutical manufacturing facility.

The expansion of the manufacturing facility is in progress with completion expected by the year 2026.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This